FDA授予Ipsen药物用于治疗不适合急性髓性白血病的突破性地位。 FDA grants breakthrough status to Ipsen’s drug for unfit acute myeloid leukemia.

美国食品和药品管理局根据早期临床数据,对Ipsen的IPN60340(ICT01)实验药物IPN60340(IPN60340)进行了“突破治疗”指认,用于对患有急性急性流血性白血病的病人进行一线治疗。 The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Ipsen’s experimental drug IPN60340 (ICT01) for use in first-line treatment of patients with unfit acute myeloid leukemia, a rare and aggressive blood cancer, based on early clinical data showing promising efficacy and safety.